Country Information


Cameroon

 
HIV prevalence 15-49, 2007/2008 5.1%
Tuberculosis death rate 31/100,000 population
Malaria death rate (children under 5) 620/100,000 population
 
   
             
     
  Cameroon is a West African nation of about 16 million people. It is relatively stable politically, and its economy, largely dependent on petroleum and cocoa exports, is strong in comparison with many other sub-saharan countries.

The HIV-burden in Cameroon is estimated at almost 12 percent of the 15-49 age population. Important HIV-related research is being conducted in Cameroon; almost every known strain of HIV, including the rare O clade HIV-1, can be found in the country (Source: CRISP database).

Malaria is endemic and is the leading cause sickness and mortality in Cameroon. It accounts for as many as half of all medical consultations, 30 percent of hospitalizations, and more than a quarter of work-days lost. Two-thirds of malaria cases in some locations are chloroquine resistant.

The WHO has estimated a tuberculosis death rate of 61 per 100,000 for the country in 2000. Nine of ten provinces are covered by Cameroon's National Tuberculosis Control Program (NTCP).

Sources: CIA World Factbook, UNAIDS, GFATM, United Nations Statistics Division

 
           
             
  Cameroon has developed a National Strategic Plan Against AIDS, and there is high level political commitment to fighting HIV/AIDS evidenced by both Cameroon's President and its Minister of Health. Priority action areas for the HIV/AIDS campaign include:
  • prevention targeting youth and women
  • involvement of employers and religious communities
  • condom distribution
  • prevention of STIs
  • blood supply safety, and
  • HIV surveillance.

Cameroon's strategic plan for fighting HIV/AIDS is expected to cost $189 million over five years; a financial gap of $110 million exists in meeting implementation costs. Cameroon is one of 13 nations taking part in the UNAIDS Accelerating Access Initiative (AAI), allowing it to purchase HIV/AIDS drugs from pharmaceutical companies at reduced prices.

Cameroon is implementing the DOTS program in its response to TB, and in 2000 WHO estimated that 75 percent of TB cases were treated under DOTS protocols. Due to a lack of funding patients receiving TB treatment have been expected to pay $7.50. A recently approved (Round 3) GFATM grant will allow for the free provision of TB treatment, and greatly increase the resources of the National TB Control Program (NTCP), which had operated without a telephone, fax, email, or vehicle.

Sources: UNAIDS, United Nations Statistics Division, GFATM

 
           
             
 
Total population. mid-2009 18.9 (millions)
HIV prevalence 15-49, 2007/2008 5.1%
Tuberculosis death rate 31/100,000 population
Prevalence of tuberculosis per 100,000 population, 2000 270
Prevalence of tuberculosis per 100,000 population, 2004 227
% Tuberculosis detection rate under DOTS, 2001 45
% Tuberculosis detection rate under DOTS, 2004 92
% Tuberculosis treatment success rate under DOTS, 2000 77
Malaria death rate (children under 5) 620/100,000 population
GNI PPP Per Capita, 2008 2,180 (US$)
Life expectancy at birth 52 years
Infant mortality rate 74/1,000 live births
Total fertility rate 4.7 per woman
Crude birth rate 36/1,000 population
Crude death rate 13/1,000 population
Adult male literacy level 92% (pct. 15+ literate)
Adult female literacy level 88% (pct. 15+ literate)
Contraceptive prevalence rate, modern methods 12% of women in union
Estimated number of people living with HIV: Adults and Children, 2005 510,000
Estimated number of people living with HIV: Adults and children, end 2003 560,000
Estimated number of people living with HIV: Adults and children, end 2001 530,000
Estimated number of people living with HIV: Adults (15+), 2005 470,000
Estimated number of people living with HIV: Adults (15-49), end 2003 520,000
Estimated number of people living with HIV: Adults (15-49), end 2001 500,000
Estimated number of people living with HIV: Adults (15-49) rate (%), 2005 5.5%
Estimated number of people living with HIV: Women (15+), 2005 290,000
Estimated number of people living with HIV: Women 15-49, end 2003 290,000
Estimated number of people living with HIV: Women 15-49, end 2001 280,000
Estimated number of people living with HIV: Children (0-14), 2005 43,000
Estimated number of people living with HIV: Children (0-14), end 2003 43,000
Estimated number of people living with HIV: Children (0-14), end 2001 39,000
Estimated number of AIDS deaths: Adults and children, 2005 46,000
AIDS deaths in adults and children, end 2003 49,000
AIDS deaths in adults and children, end 2001 41,000
Estimated number of orphans due to AIDS: Children (0-17), 2005 240,000
Orphans due to AIDS (0-17), living 2003 240,000
Orphans due to AIDS (0-17), living 2001 170,000
% Women (15-49), currently married or living with a partner, who have ever discussed AIDS prevention with their husband or partner 59%

Demographic data contained in this section was obtained from the following sources: The Population Reference Bureau’s 2009 World Population Data Sheet was used for total population, life expectancy at birth, infant mortality, fertility, birth rate, death rate, % of married women 15-49 using modern methods of contraception, % of population 15-49 with HIV/AIDS in 2007/2008, and the GNI PPP per capita (2008). Literacy rates were found in the Population Reference Bureau’s publication 2005 Women of Our World. HIV prevalence data for 2001 and 2003 was obtained from the UNAIDS Barcelona 2002 report; HIV prevalence and orphan data for 2005 was obtained from the UNAIDS Report on the Global AIDS Epidemic 2006. Data on the % women who have discussed AIDS prevention with their husband or partner can be found in ORC Macro and USAID’s Women’s Lives and Experiences: Changes in the Past Ten Years (Research Findings from the Demographic and Health Surveys). Childhood malaria mortality data was accessed in 2003 from the United Nations Statistics Divisions’ Millennium Indicators. Tuberculosis data was obtained from the United Nations Statistics Division’s Millennium Indicators: MDGInfo 2006. In some cases information was unavailable.

 
           
             
  Cameroon's public health care system includes:
  • 1 university teaching hospital
  • 3 central hospitals
  • 10 private hospitals
  • 136 district hospitals

In addition there are public medical centers, mission hospitals, and there are some private clinics and hospitals. Cameroon has 18 approved treatment centers with the capacity to provide HAART treatment for PLWHA. The Ministry of Public Health's annual budget for 1998/1999 was $6.35 million.

The WHO estimates that Cameroon had 7.4 physicians and 36.7 nurses per 100,000 population in 1996.

Sources: Ako et al, Reproductive Health in Cameroon, WHO

 
           
             
 

Ministry of Public Health

Organization de Coordination pour la lutte contre les Endemies en Afrique Centrale (OCEAC)

OCEAC is one of about 30 research institutions in Africa identified by the African Malaria Vaccine Testing Network (AMVTN) as having the capabilities to support malaria vaccine trials. OCEAC has about 25 staff, including four medical doctors and two PhDs. August Bilongo-Manene is OCEAC's Secretary General.

Source: AMVTN

University of Yaounde, Faculty of Medicine

 
           
             
 

Entity

Project Title

Diseases

Primary Category

Secondary Category

NIH Drug Development and Conservation of Biodiversity in West-central Africa HIV/AIDS,Malaria Drug Development  
  (Principal Investigator: Brian Schuster. 1998-2003.) This project, directed by Colonel Brian Schuster of Walter Reed Army Hospital, has developed a...

NIH Clinical and Mucosal Interactions Between HSV and HIV HIV/AIDS Drug Development Prevention
  (PI: Lawrence Corey. 2003-2008.) This research project includes a double blind cross over study of the efficacy of daily acyclovir treatment in...

NIH Evolution and Properties of HIV/SIV Strains in Cameroon HIV/AIDS Epidemiology  
  (PI: Phillipe Nyambi. 2000-2004.) This study investigates possible cross-species transmission of the M, N and O varieties of HIV-1. It also examines...

NIH Immunologic Characteristics of HIV Isolates in Cameroon HIV/AIDS Epidemiology  
  (PI: Phillipe Nyambi. 2000-2003.) This study compares immunological characteristics of HIV-1 clades A-J in Cameroon.

NIH The Emergence of HIV Genetic Diversity in Cameroon HIV/AIDS Epidemiology  
  (PI: Nathan Wolfe. 1999-2003.) This study investigates the relationship between lentiviruses found among primate hunters in Cameroon, and the...

NIH Virus-cell interaction/host factors in HIV pathogenesis HIV/AIDS Epidemiology  
  (PI: Indira Hewlett. 2002) A component of this study is investigating new strategies for the identifications of new variants and recombinants of HIV...

NIH Detection, quantitation and characterization of HIV HIV/AIDS Epidemiology  
  (PI: Indira Hewlett. 2002) This study is examining the molecular evolution of various strains of HIV found in Cameroon.

NIH Immunologic Relatedness Among and Between HIV1 Clades HIV/AIDS Epidemiology Drug Development
  (PI: Susan Zolla-Pazner. 1994-2004.) The objective of this study includes analyzing human monoclonal antibodies (mAbs) from blood specimens...

NIH Natural SIV reservoirs and human zoonitic risk HIV/AIDS Epidemiology  
  (PI: Beatrice Hahn. 2001-2006.) This study aims to determine the full spectrum and prevalence of SIV in both human and non-human populations in...

NIH Genetic Variation in HIV Disease HIV/AIDS Epidemiology Drug Development
  (PI: Indira Hewlitt. 2003?) This grant covers several different research activities relating to genetically diverse strains of HIV found in...

NIH Population genomics of Mosquito An. gambiae in Africa Malaria Epidemiology Prevention
  (PI: Gregory Lanzaro. 1996-2007.) This study examines population size, patterns of gene flow and breeding stucture for the populations of mosquito...

NIH Th2 Bias Effect On Malarial Immunity in Cameroon Malaria Epidemiology  
  (PI: Diane Taylor. 1998-2005.) This study examines the effect of body-chemistry changes during pregnancy on naturally occurring malarial immunity...

NIH Malarial Immunity in Pregnant Cameronian Women Malaria Prevention  
  National Institute of Allergy and Infectious Diseases, University of Hawaii, University of Yaounde. The Ministry of Health in Cameroon has...

NIH Fogarty AIDS International Training & Research Program HIV/AIDS Capacity  
  (PI: Chris Beyrer. 1998-2008.) This Fogarty grant allows Johnns Hopkins University to provide training to 1 long-term trainee, 34 short-term...

NIH Training Program in TB and HIV Prevention and Treatment HIV/AIDS,Tuberculosis Capacity Prevention
  (PI: Susan Zolla-Pazner. 2000-2005.) This program of the NYU Center for AIDS Research supports clinical and research training for scientists and...

International DFID (The United Kingdom) HIV/AIDS,Tuberculosis Drug Development Prevention,Capacity
  In 2002 DFID announced a five-year $23 million study in Cameroon and several other African nations to develop a microbicide effective against HIV...

International Molecular Diversity of HIV-1 Group 0 Strains and Treatment Management in Cameroon HIV/AIDS Drug Development General
  French National Agency for Research on AIDS and Viral Hepatitis, Hôpital Central, Hôpital Militaire, Hôpital Général, Hôpital de la CNPS (PI:...

International Evaluation of Three Strategies of Second-Line Antiretroviral Treatment in Africa (Dakar-Bobo-Dioulasso-Yaoundé) (2LADY) HIV/AIDS Drug Development  
  French National Agency for Research on AIDS and Viral Hepatitis, Gilead Sciences, Janssen Pharmaceutica N.V. Belgium (PIs: Sinata Koulla Shiro,...

International Evaluation of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Africa (ANRS 12115 DAYANA) HIV/AIDS Drug Development  
  French National Agency for Research on AIDS and Viral Hepatitis (PIs: Landman Roland, Sow Papa Salif, Koulla Shiro Sinata). This trial will enroll...

International Safety, Tolerance and Acceptability Trial of the Invisible Condom® in Healthy Women HIV/AIDS Drug Development Prevention
  Laval University, Canadian Institutes of Health Research, Centre Hospitalier de l'Universite Laval. (PI: Michel Bergeron). This trial will allow...

International ATAQ Easy: Artesunate + Amodiaquine Fixed Dose Combination in the Treatment of Uncomplicated Plasmodium Falciparum Malaria Malaria Drug Development  
  Sanofi-Aventis (Study Director: Valérie Lameyre). This study will compare and contrast the efficacy of three treatment regimens for malaria in...

International Multisectoral HIV/AIDS Project (World Bank) HIV/AIDS Capacity  
  The World Bank is providing $50 million for a Multisectoral HIV/AIDS Project to be implemented over the 2001-2005 period. The project information...

International Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) HIV/AIDS,Tuberculosis,Malaria General  
  GFATM has appropriated $34.6 million over two years for fighting these contagious diseases in Cameroon. The appropriations included:
  • $17
...

NGO A Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Acyclovir for Suppression of HSV and HIV Shedding in HIV-1, HSV-2 Coinfected Persons in Cameroon. HIV/AIDS Drug Development Prevention
  Fred Hutchinson Cancer Research Center Institute for the Development of Africa. (PI: Francois Xavier Mbopi-Keou; study start March 2005). In this...

NGO MIM/TDR Grants for Malaria Research Malaria Epidemiology  
  A Multilateral Initiative on Malaria (MIM)/TDR Task Force awarded one grant in the amount of $77,000 for malaria research in Cameroon in 2002. The...

Foundation Artemisinin-Based Combination Therapy: Clinical Trials in Cameroon Malaria Drug Development  
  Gates Malaria Partnership (PI: Wilfred F. Mbacham). This study will compare the effectiveness and safety of Artemisinin-based combination therapy...

 
           
             
  No information available  
           



Home || HIV/AIDS || Tuberculosis || Malaria || Advanced Search || Links || Contact Us

Last site update: September 03, 2009

For questions, or to report problems with this site, please contact the Webmaster.

Disclaimer